期刊
THORACIC CANCER
卷 13, 期 15, 页码 2142-2151出版社
WILEY
DOI: 10.1111/1759-7714.14527
关键词
ATP-binding cassette transporters; drug resistance; small cell lung cancer; topoisomerase I inhibitor; topoisomerase II inhibitor
资金
- Ministry of Education, Culture, Sports, Science, and Technology of Japan [16K09561, 16K09592]
- Ministry of Education
- Grants-in-Aid for Scientific Research [16K09561, 16K09592] Funding Source: KAKEN
This study identified key factors in the chemoresistance of SCLC, including drug efflux proteins ABCB1 and ABCG2. Inhibiting these proteins can restore drug sensitivity and promote apoptotic activity in SCLC cells. ABC transporter inhibitors may be a promising therapeutic strategy for overcoming resistance to topoisomerase inhibitors in SCLC patients.
Background Small cell lung cancer (SCLC) is a highly aggressive disease with a poor prognosis. Although most patients initially respond to topoisomerase inhibitors, resistance rapidly emerges. The aim, therefore, is to overcome resistance to topoisomerase I (irinotecan) or II (etoposide) inhibitors in SCLCs. Methods To identify key factors in the chemoresistance of SCLCs, we established four cell lines resistant to etoposide or an active metabolite of irinotecan, SN-38, from SCLC cell lines and evaluated RNA profiles using parental and newly established cell lines. Results We found that the drug efflux protein, ATP-binding cassette sub-family B member 1 (ABCB1), was associated with resistance to etoposide, and ATP-binding cassette sub-family G member 2 (ABCG2) was associated with resistance to SN-38 by RNA sequencing. The inhibition of ABCB1 or ABCG2 in each resistant cell line induced synergistic apoptotic activity and promoted drug sensitivity in resistant SCLC cells. The ABC transporter inhibitors, elacridar and tariquidar, restored sensitivity to etoposide or SN-38 in in vitro and in vivo studies, and promoted apoptotic activity and G2-M arrest in resistant SCLC cells. Conclusions ABC transporter inhibitors may be a promising therapeutic strategy for the purpose of overcoming resistance to topoisomerase inhibitors in patients with SCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据